Table 1 Baseline characteristics
Losartan group | LS/HCTZ group | P-value | |
|---|---|---|---|
Number (n) | 48 | 51 | |
Age (year) | 58±12 | 58±11 | 0.90 |
Sex (male/female) | 26/22 | 30/21 | 0.61 |
Underlying kidney disease, n (%) | |||
Glomerulonephritis | 39 (81) | 41 (80) | 0.82 |
Diabetic nephropathy | 4 (8) | 6 (12) | |
Hypertensive nephrosclerosis | 5 (11) | 5 (8) | |
Systolic blood pressure (mm Hg) | 132±14 | 128±13 | 0.16 |
Diastolic blood pressure (mm Hg) | 77±9 | 77±12 | 0.84 |
Pulse rate (beats min−1) | 73±10 | 73±11 | 0.82 |
Total protein (g dl−1) | 6.9±0.6 | 6.9±0.5 | 0.55 |
Albumin (g dl−1) | 4.0±0.4 | 3.9±0.4 | 0.10 |
HDL-cholesterol (mg dl−1) | 65±35 | 61±26 | 0.73 |
LDL-cholesterol (mg dl−1) | 119±35 | 112±27 | 0.42 |
Triglycerides (mg dl−1) | 157±83 | 154±76 | 0.83 |
Blood urea nitrogen (mg dl−1) | 24±11 | 25±11 | 0.74 |
Creatinine (mg dl−1) | 1.4±0.7 | 1.5±0.7 | 0.68 |
Uric acid (mg dl−1) | 6.6±1.4 | 6.6±1.3 | 0.89 |
Sodium (mEq l−1) | 138±2 | 141±2 | 0.18 |
Potassium (mEq l−1) | 4.6±0.5 | 4.6±0.5 | 0.82 |
Chloride (mEq l−1) | 106±2.6 | 107±2.7 | 0.34 |
Calcium (mg dl−1) | 9.2±0.4 | 9.2±0.5 | 0.70 |
Phosphate (mg dl−1) | 3.4±0.6 | 3.3±0.6 | 0.72 |
Aspartate aminotransferase (U l−1) | 22±6.1 | 21±5.2 | 0.89 |
Alanine aminotransferase (U l−1) | 20±9.3 | 17±8.9 | 0.14 |
Alkaline phosphatase (U l−1) | 237±79 | 225±65 | 0.65 |
γ-Glutamyl transpeptidase (U l−1) | 43±29 | 38±37 | 0.14 |
eGFR (ml min−1 per 1.73 m2) | 45.9±25.1 | 43.8±21.9 | 0.67 |
Urinary protein/creatinine ratio (g g−1 Cr) | 1.80±1.63 | 1.74±1.40 | 0.52 |
Treatment during pretreatment period, n (%) | |||
Ca channel blockers | 24 (50) | 22 (43) | 0.42 |
β-Blockers | 3 (6) | 7 (14) | 0.43 |
α-Blockers | 2 (4) | 1 (2) | 0.51 |
Statins | 21 (44) | 17 (33) | 0.96 |
